Molecular structure of Brimonidine Tartrate, CAS Number: 70359-46-5
Brimonidine Tartrate (CAS 70359-46-5)
See product citations (4)
Alternate Names:
5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-6-quinoxalinamine tartrate
Application:
Brimonidine Tartrate is an α-2 receptor agonist
CAS Number:
70359-46-5
Purity:
≥99%
Molecular Weight:
442.22
Molecular Formula:
C15H16BrN5O6
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Brimonidine Tartrate is an AR (alpha 2 receptor) agonist that acts via decreasing aqueous humor synthesis. In research applications, Brimonidine Tartrate′s ability to bind to and activate alpha adrenergic receptors makes it useful for understanding the modulation of these receptors and their role in physiological processes. in vitro studies are used to investigate its effects on cell proliferation in culture, on regulation of intracellular calcium in cells, and on the regulation of cell death. It has also been used to study its effects on the regulation of gene expression in cells, and to investigate its effects on the regulation of cell adhesion. Brimonidine Tartrate is an imidazoline derivative.
Brimonidine Tartrate (CAS 70359-46-5) References
- In vitro characterization of a controlled-release ocular insert for delivery of brimonidine tartrate. | Mealy, JE., et al. 2014. Acta Biomater. 10: 87-93. PMID: 24080317
- Brimonidine tartrate for the treatment of facial flushing and erythema in rosacea. | Tong, LX. and Moore, AY. 2014. Expert Rev Clin Pharmacol. 7: 567-77. PMID: 25091290
- Increasing efficacy and reducing systemic absorption of brimonidine tartrate ophthalmic gels in rabbits. | Pang, X., et al. 2018. Pharm Dev Technol. 23: 231-239. PMID: 28488447
- Inhibition of mast cell infiltration in an LL-37-induced rosacea mouse model using topical brimonidine tartrate 0.33% gel. | Kim, M., et al. 2017. Exp Dermatol. 26: 1143-1145. PMID: 28500634
- Sedative and physiological effects of brimonidine tartrate ophthalmic solution in healthy cats. | Ogata, N., et al. 2017. Vet Anaesth Analg. 44: 1091-1100. PMID: 28865952
- Severe Corneal Disorders Developed After Brimonidine Tartrate Ophthalmic Solution Use. | Maruyama, Y., et al. 2017. Cornea. 36: 1567-1569. PMID: 28938378
- Comparison of the neuroprotective effects of brimonidine tartrate and melatonin on retinal ganglion cells. | Marangoz, D., et al. 2018. Int Ophthalmol. 38: 2553-2562. PMID: 29159432
- Impact of Ocular Compatible Lipoids and Castor Oil in Fabrication of Brimonidine Tartrate Nanoemulsions by 33 Full Factorial Design. | Rimple,. and Newton, MJ. 2018. Recent Pat Inflamm Allergy Drug Discov. 12: 169-183. PMID: 30058499
- Brimonidine tartrate for the treatment of glaucoma. | Oh, DJ., et al. 2019. Expert Opin Pharmacother. 20: 115-122. PMID: 30407890
- Effect of brimonidine tartrate 0.15% on scotopic pupil size and upper eyelid position: controlled trial. | Tuncer, I., et al. 2021. Eye (Lond). 35: 672-675. PMID: 32518394
- Isolation and characterization of thermal degradation impurity in brimonidine tartrate by HPLC, LC-MS/MS, and 2DNMR. | Baksam, V., et al. 2021. J Pharm Biomed Anal. 205: 114297. PMID: 34391137
- Post-acne erythema treatment: A systematic review of the literature. | Kalantari, Y., et al. 2022. J Cosmet Dermatol. 21: 1379-1392. PMID: 35076997
- Brimonidine tartrate ophthalmic solution 0.025% for redness relief: an overview of safety and efficacy. | Lee, JS. and Kim, CY. 2022. Expert Rev Clin Pharmacol. 15: 911-919. PMID: 35951740
Activator of:
AR.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Brimonidine Tartrate, 100 mg | sc-217788 | 100 mg | $176.00 |